Close Menu

NEW YORK – Fluidigm this week announced that the Central Drugs Standard Control Organisation (CDSCO) in India has licensed importation and sale of its Advanta Dx SARS-CoV-2 RT-PCR Assay, one of the first saliva-based tests to be licensed for COVID-19 testing in India. The license granted to Premas Life Sciences, a Delhi-based life sciences distribution company, enables use of the test in laboratories approved by the Indian Council of Medical Research or a relevant state or central government.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.